Mar Rhino (Xylometazoline Hydrochloride)

Xylometazoline Hydrochloride is a selective alpha‑adrenergic agonist. When applied to the nasal mucosa it stimulates alpha‑adrenergic receptors on vascular smooth muscle, causing vasoconstriction. This reduces blood flow to the nasal tissues, decreasing edema and opening the airway.

The specific dose is determined by the prescribing clinician. In typical practice, adults may use one to two sprays per nostril every 8‑10 hours, not exceeding the maximum daily frequency indicated on the product label, and treatment should not extend beyond three to five days.

Safety data for Xylometazoline Hydrochloride during pregnancy and lactation are limited. It is classified as pregnancy category unknown, so it should only be used if the potential benefit justifies the potential risk and after consultation with a qualified healthcare professional.

To place an order, submit an enquiry on the Mar Rhino product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mar Rhino’s active ingredient, Xylometazoline, has a rapid onset and a duration of action similar to oxymetazoline, another common topical decongestant. Both act via alpha‑adrenergic vasoconstriction, but Xylometazoline may be preferred in some markets for its slightly longer half‑life, while the safety profile remains comparable.

Store Mar Rhino at room temperature, ideally below 25 °C, in its original packaging. Protect the container from moisture, excessive heat and direct sunlight. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Mar Rhino is administered intranasally. The user should gently blow the nose, tilt the head slightly forward, insert the spray tip into one nostril, and press the actuator to deliver the prescribed number of sprays. The same procedure is repeated for the other nostril if required.

Serious risks include rebound nasal congestion (rhinitis medicamentosa) after prolonged use, significant elevation of blood pressure or heart rate, and rare severe allergic reactions such as anaphylaxis. If any of these occur, discontinue use immediately and seek medical attention.

Mar Rhino should be avoided in children younger than two years, patients with severe hypertension, those taking monoamine oxidase inhibitors, or individuals with known hypersensitivity to Xylometazoline or any excipients in the formulation. Consultation with a healthcare provider is essential before use in these groups.